The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenedrive Regulatory News (GDR)

Share Price Information for Genedrive (GDR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.95
Bid: 1.90
Ask: 2.00
Change: -0.50 (-20.00%)
Spread: 0.10 (5.263%)
Open: 2.225
High: 2.075
Low: 2.00
Prev. Close: 2.50
GDR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Application for Block Listing

28 May 2020 13:18

RNS Number : 2525O
Genedrive PLC
28 May 2020
 

genedrive plc

("genedrive" or the "Company")

 

Application for Block Listing

 

genedrive plc (LSE: GDR), the near patient molecular diagnostics company, today announces that an application has been made to the London Stock Exchange for a block listing of 300,000 new ordinary shares of 1.5p each ('Ordinary Shares') in genedrive in respect of Ordinary Shares that are to be allotted under the genedrive 2007 Share Option Scheme.

 

It is expected that the 300,000 Ordinary Shares will be admitted to trading on 4 June 2020. The shares will rank pari passu with the existing Ordinary Shares of the Company.

 

 

genedrive plc

+44 (0)161 989 0245

David Budd: CEO / Matthew Fowler: CFO

Peel Hunt LLP (Nominated Adviser and Joint Broker)

+44 (0)20 7418 8900

James Steel / Oliver Jackson

finnCap (Joint Broker)

+44 (0)20 7220 0500

Geoff Nash / Kate Bannatyne / Alice Lane

Walbrook PR Ltd (Media & Investor Relations)

+44 (0)20 7933 8780 or genedrive@walbrookpr.com

Paul McManus / Anna Dunphy

+44 (0)7980 541 893 / +44 (0)7876 741 001

 

 

About genedrive plc (http://www.genedriveplc.com)

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company has assays on market for the detection of HCV, certain military biological targets, and has tests in development for tuberculosis (mTB). The Company recently announced the development of a high throughput SARS-CoV-2 assay and a Genedrive® Point of Care version of the assay, both based on Genedrive® PCR chemistry.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
ALSSEWFEAESSEFI
Date   Source Headline
9th Dec 20219:05 amRNSSecond Price Monitoring Extn
9th Dec 20219:00 amRNSPrice Monitoring Extension
8th Dec 20214:40 pmRNSSecond Price Monitoring Extn
8th Dec 20214:35 pmRNSPrice Monitoring Extension
8th Dec 20212:05 pmRNSSecond Price Monitoring Extn
8th Dec 20212:00 pmRNSPrice Monitoring Extension
8th Dec 202112:31 pmRNSCE-IVD certification for Point-of-Care kit
7th Dec 20219:00 amRNSPrice Monitoring Extension
7th Dec 20217:00 amRNSHolding(s) in Company
6th Dec 20214:43 pmRNSAdditional Listing of Shares
6th Dec 20212:05 pmRNSSecond Price Monitoring Extn
6th Dec 20212:00 pmRNSPrice Monitoring Extension
2nd Dec 20219:44 amRNSGrant of options
2nd Dec 20219:05 amRNSSecond Price Monitoring Extn
2nd Dec 20219:00 amRNSPrice Monitoring Extension
30th Nov 202111:05 amRNSSecond Price Monitoring Extn
30th Nov 202111:00 amRNSPrice Monitoring Extension
29th Nov 20214:41 pmRNSSecond Price Monitoring Extn
29th Nov 20214:36 pmRNSPrice Monitoring Extension
29th Nov 20212:06 pmRNSSecond Price Monitoring Extn
29th Nov 20212:01 pmRNSPrice Monitoring Extension
29th Nov 202110:32 amRNSBlock listing Interim Review
29th Nov 20217:00 amRNSPOC kit submitted for CE-IVD certification
26th Nov 20214:41 pmRNSSecond Price Monitoring Extn
26th Nov 20214:36 pmRNSPrice Monitoring Extension
17th Nov 20217:00 amRNSAnnual Report and Accounts and notice of AGM
16th Nov 20217:00 amRNSDirectorate Change
9th Nov 20217:00 amRNSFinal Results
28th Oct 20213:40 pmRNSNotice of Results
11th Oct 20217:00 amRNSDirector's shareholding
30th Sep 20211:00 pmRNSResult of General Meeting
29th Sep 20217:00 amRNSResult of Open Offer
29th Sep 20217:00 amRNSNew Genedrive System receives CE-IVD marking
14th Sep 20217:00 amRNSPublication of Circular and Notice of GM
10th Sep 20215:03 pmRNSResult of Placing
10th Sep 20214:40 pmRNSSecond Price Monitoring Extn
10th Sep 20214:35 pmRNSPrice Monitoring Extension
10th Sep 20212:01 pmRNSProposed Placing and Open Offer
31st Aug 20217:00 amRNSNew Genedrive system readied for AIHL launch
1st Jul 20217:00 amRNSGenedrive COVID-19 Point of Care device update
25th Jun 20214:40 pmRNSSecond Price Monitoring Extn
25th Jun 20214:35 pmRNSPrice Monitoring Extension
25th Jun 20211:17 pmRNSGenedrive confirms receipt of India Import License
25th Jun 202111:05 amRNSSecond Price Monitoring Extn
25th Jun 202111:00 amRNSPrice Monitoring Extension
22nd Jun 202111:05 amRNSSecond Price Monitoring Extn
22nd Jun 202111:00 amRNSPrice Monitoring Extension
28th May 20216:00 pmRNSBlock listing Interim Review
28th May 20214:40 pmRNSSecond Price Monitoring Extn
28th May 20214:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.